{"nctId":"NCT03764735","briefTitle":"Study of SkQ1 as Treatment for Dry-eye Syndrome","startDateStruct":{"date":"2018-12-06","type":"ACTUAL"},"conditions":["Dry Eye Syndrome"],"count":452,"armGroups":[{"label":"SkQ1 Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: SkQ1 (Vehicle)"]},{"label":"Low Dose - SkQ1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Low Dose - SkQ1"]},{"label":"High Dose - SkQ1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: High dose - SkQ1"]}],"interventions":[{"name":"Low Dose - SkQ1","otherNames":["Visomitin"]},{"name":"High dose - SkQ1","otherNames":["Visomitin"]},{"name":"SkQ1 (Vehicle)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be at least 18 years of age;\n* Provide written informed consent;\n* Have a subject reported history of dry eye;\n* Have a history of use of eye drops for dry eye symptoms ;\n* Ocular Discomfort;\n* Schirmer's Test score;\n* Have corneal fluorescein staining ;\n* Have lissamine green conjunctival Staining ;\n* Have a conjunctival redness;\n\nExclusion Criteria:\n\n* Have participated in the previous SkQ1 ophthalmic solution Phase 2 treatment study;\n* Have any clinically significant slit lamp findings at Visit 1;\n* Be diagnosed with an ongoing ocular infection or active ocular inflammation at Visit 1;\n* Have had any ocular and/or lid surgeries within 6 months of Visit 1 or any planned over the study period;\n* Have an uncontrolled systemic disease;\n* Be a woman who is pregnant, nursing or planning a pregnancy;\n* Be a woman of childbearing potential who is not using an acceptable means of birth control;\n* Have a known allergy and/or sensitivity to the study drug or its components ;\n* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;\n* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Central Corneal Staining Change From Baseline","description":"Change of Corneal Fluorescein Staining from baseline to Day 57, scale ranges from 0 to 4, where grade 0 = None, 4 = Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.773"},{"groupId":"OG001","value":"-0.3","spread":"0.816"},{"groupId":"OG002","value":"-0.2","spread":"0.763"}]}]}]},{"type":"PRIMARY","title":"Grittiness Change From Baseline","description":"Change of patient-reported grittiness from baseline to Day 57, scale ranges from 0 to 5 for each symptom, where 0 = None and 5 = Worst","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"1.108"},{"groupId":"OG001","value":"-0.36","spread":"1.176"},{"groupId":"OG002","value":"-0.43","spread":"1.387"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":151},"commonTop":["Instillation site pain","Visual acuity reduced"]}}}